Considerations of Sex and Gender in FDA Tobacco Regulation

Danielle R Davis; Suchitra Krishnan-Sarin; Carolyn M Mazure

doi:10.1001/jama.2023.6803

Considerations of Sex and Gender in FDA Tobacco Regulation

JAMA. 2023 Jun 20;329(23):2017-2018. doi: 10.1001/jama.2023.6803.

Authors

Danielle R Davis¹, Suchitra Krishnan-Sarin¹, Carolyn M Mazure^{1

2}

Affiliations

¹ Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
² Department of Psychology, Yale School of Medicine, New Haven, Connecticut.

PMID: 37233997
DOI: 10.1001/jama.2023.6803

No abstract available

Plain language summary

This Viewpoint discusses how sex and gender subpopulations may be differentially affected by tobacco products and suggests that the FDA formulate regulations in clinically meaningful ways.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Female
Gender Identity
Government Regulation
Humans
Male
Sex Factors
Tobacco Control*
Tobacco Industry*
Tobacco Products* / legislation & jurisprudence
United States
United States Food and Drug Administration / legislation & jurisprudence

Plain language summary

Publication types

MeSH terms

Grants and funding